Antengene’s Xpovio Receives Marketing Approval in Indonesia
China-based biopharma Antengene Corp., Ltd (HKG: 6996) announced receiving marketing approval in Indonesia for its...
HKG: 6996
Antengene to Boost T Cell Engager Platform with AI Investment and DeepSeek Deployment
China-based biopharma Antengene Corp., Ltd (HKG: 6996) announced plans to increase investment in establishing a...
Antengene’s Xpovio Included in Taiwan’s NHI Drug List for Myeloma Treatment
China-based biopharma Antengene Corp., Ltd (HKG: 6996) announced that its Xpovio (selinexor), the world’s first...
Antengene’s Xpovio Showcases Positive Results in Phase III BENCH and Phase I/II TOUCH Studies at ASH 2024
China-based Antengene Corporation Limited (Antengene, HKG: 6996) announced the presentation of the latest results from...
Antengene’s Xpovio Receives NDA Approval in Thailand for Multiple Myeloma Treatment
Antengene Corp., Ltd (HKG: 6996), a biopharmaceutical company based in China, has announced that it...
Antengene’s Xpovio Receives NDA Approval in Malaysia for Multiple Myeloma Treatment
Antengene Corp., Ltd (HKG: 6996), a biopharmaceutical company based in China, has announced the approval...
Antengene’s Xpovio Secures NMPA Approval for R/R Diffuse Large B-Cell Lymphoma
Antengene Corp., Ltd (HKG: 6996), a biopharmaceutical company based in China, has announced that it...
Antengene’s Xpovio Included in South Korea’s NHIS Reimbursement Drug List
Antengene Corp., Ltd (HKG: 6996), a biopharmaceutical company based in China, has announced that South...
Antengene’s ATG-022 Advances to Dose Expansion Phase in Phase II CLINCH Study for Solid Tumors
Antengene Corporation Ltd (HKG: 6996), a leading biopharmaceutical company based in China, has announced that...
Antengene Secures NDA Approval for Xpovio in Macau for Advanced Multiple Myeloma
Antengene Corp., Ltd. (HKG: 6996), a biopharmaceutical company based in China, has announced that it...
Antengene’s Anti-CD24 Antibody ATG-031 Gets Green Light for Phase I Study at MD Anderson
Antengene Corporation Ltd (HKG: 6996), a China-based biopharmaceutical company, has announced that the Institutional Review...
Antengene’s Xpovio Price Reduced by 37% in China, Aiding Patient Access
Antengene Corp., Ltd (HKG: 6996) has announced a significant price reduction for its drug Xpovio...
Antengene Corp. Secures Licensing Deal with Hansoh Pharmaceutical for Xpovio in China
China-based biopharmaceutical company Antengene Corp., Ltd (HKG: 6996) has announced a significant licensing agreement with...
Antengene Corp. Receives FDA Fast-Track Designation for Xpovio in Myelofibrosis Treatment
China-based biopharma Antengene Corp., Ltd (HKG: 6996) has announced receiving fast-track designation from the US...
Antengene Initiates Phase I ERASER Study for ATG-017 in Combination with Nivolumab
China-based biopharmaceutical company Antengene Corp., Ltd (HKG: 6996) has announced the first patient dosing in...
Antengene Corp., Ltd Receives Hong Kong NDA Approval for Xpovio in Relapsed Multiple Myeloma
China-based biopharmaceutical company Antengene Corp., Ltd (HKG: 6996) has announced receiving New Drug Application (NDA)...
Antengene’s Xpovio Combination Therapy Approved for Reimbursement in Australia for R/R MM
China-based biotech Antengene Corp., Ltd (HKG: 6996) has revealed that Australia’s Pharmaceutical Benefits Scheme (PBS)...
Antengene’s ATG-022 Earns FDA Orphan Drug Designations for Gastric and Pancreatic Cancers
China-based Antengene Corporation Limited (HKG: 6996) has announced that its in-house discovered and developed antibody...
Antengene’s First-in-Class CD24 mAb ATG-031 Gets US FDA Approval for Phase I Study
Antengene Corp., Ltd (HKG: 6996) has announced that it has received approval from the US...
Antengene Submits Market Approval Filing for Xpovio in Indonesia for Multiple Myeloma and Lymphoma
Antengene Corp., Ltd (HKG: 6996) has announced a market approval filing in Indonesia for its...